Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Cytomegalovirus (CMV) infection is a common viral infection that can remain latent in the body and cause complications in immunocompromised individuals and newborns. According to Cytogam, global CMV seroprevalence is estimated at 83% in the general population, compared with 75% among adults in the United States. According to cytomegalovirus (CMV) infection epidemiology forecast by Expert Market Research, these figures highlight the disease's widespread prevalence and epidemiological significance.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Cytomegalovirus (CMV) Infection – Number of Cases by Year

Read more about this report - Request a Free Sample

Cytomegalovirus (CMV) Infection Epidemiology Forecast Report Coverage

Expert Market Research's “Cytomegalovirus (CMV) Infection Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of cytomegalovirus (CMV) infection. It projects the future incidence and prevalence rates of cytomegalovirus (CMV) infection cases across various populations. The study covers age, gender, and type as major determinants of the cytomegalovirus (CMV) infection population. The report highlights patterns in the prevalence of cytomegalovirus (CMV) infection over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of cytomegalovirus (CMV) infection in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Cytomegalovirus (CMV) Infection Understanding: Disease Overview

Cytomegalovirus (CMV) infection is caused by human herpesvirus 5, a member of the Herpesviridae family. The virus spreads through infected bodily fluids, including saliva, urine, blood, and genital secretions, and remains latent in the body after the initial infection. Infection may occur as a primary infection, reactivation of a latent virus, or reinfection with a different strain. Congenital CMV infection occurs when the virus is transmitted from a pregnant woman to her fetus. Although infection is often asymptomatic, viral reactivation can cause serious complications in immunocompromised individuals, including transplant recipients.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Immunocompromised individuals, solid organ transplant recipients, pregnant women, and infants with congenital CMV infection represent important populations for monitoring and intervention.

Key Diagnostic Method

Polymerase chain reaction testing can detect CMV DNA in appropriate clinical specimens. Serological testing, including immunoglobulin G, immunoglobulin M, and immunoglobulin G avidity testing, supports assessment in relevant settings.

Major Risk Factor

Immunosuppression increases the risk of clinically significant CMV disease. Exposure to infected bodily fluids and maternal infection or reactivation during pregnancy are also important epidemiological considerations.

Major gap in the market

Limited awareness, gaps in congenital CMV detection, and the need for improved risk assessment and monitoring among transplant recipients create opportunities for enhanced screening and diagnostic approaches.

Cytomegalovirus (CMV) Infection Epidemiology Perspective

The cytomegalovirus (CMV) Infection epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the cytomegalovirus (CMV) Infection epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cytomegalovirus (CMV) Infection and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Cytogam, global CMV seroprevalence is estimated at 83%, while approximately 75% of adults in the United States are seropositive. CMV infection persists throughout life, and prevalence generally increases with age.

Gender-Specific Cases of the Disease

According to Karen Fowler et al. (2022), CMV immunoglobulin G seroprevalence among adult men ranged from 39.3% in France to 48.0% in the United States. Among women of reproductive age, seroprevalence varied across regions, reflecting differences in population characteristics and exposure.

Age-Specific Cases of the Disease

According to the Centers for Disease Control and Prevention, nearly one in three children in the United States is infected with CMV by age five, and more than half of adults have been infected by age 40. Seroprevalence generally increases with age.

Ethnicity-Wise Cases of the Disease

According to Karen Fowler et al. (2022), CMV seroprevalence is associated with race, ethnicity, socioeconomic status, and educational attainment. Differences in exposure and population characteristics contribute to variations in seroprevalence across demographic groups and geographical regions.

Mortality and Survival Analysis of the Disease

According to Saravana Priya J. K. et al. (2024), CMV infection among post-renal transplant recipients was associated with graft dysfunction and rejection. Congenital CMV can also result in long-term health complications, including hearing loss, visual impairment, and intellectual disability.

Cytomegalovirus (CMV) Infection – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Cytomegalovirus (CMV) Infection Epidemiology

The cytomegalovirus (CMV) Infection epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to Cytogam, approximately 75% of adults in the United States are CMV-seropositive. The Centers for Disease Control and Prevention reports that nearly one in three children is infected by age five, more than half of adults have been infected by age 40, and approximately one in 200 babies is born with congenital CMV infection.

Germany

According to the German Center for Infection Research (DZIF), approximately 70% of adults in Germany carry CMV. Infection is generally asymptomatic but can become clinically significant in individuals with weakened immune systems, including transplant recipients. Maternal infection during pregnancy is also relevant because congenital transmission can affect fetal and neonatal health.

France

According to Karen Fowler et al. (2022), CMV immunoglobulin G seroprevalence among adult men in France was 39.3%. The study also reported that CMV seroprevalence among women of reproductive age varied across European populations, ranging from 45.6% to 95.7%.

Italy

According to Valeria Rubinacci et al. (2022), the incidence of congenital CMV infection in Italy ranges from 0.57% to 1% of live births. Limited awareness among the general population, healthcare professionals, and pregnant women remains a relevant consideration in understanding the burden of congenital infection.

Spain

According to Maria Angeles Sanchez-Durán et al. (2023), the reported prevalence of congenital CMV infection in Spain is 0.47%, equivalent to approximately one in 200 newborns. Transmission can occur following primary maternal infection or through reactivation or reinfection during pregnancy.

United Kingdom

According to H. Payne et al. (2025), analysis of more than 3,345 stored newborn dried blood spot samples indicated a potential congenital CMV prevalence of 0.66% in the United Kingdom. The findings highlight the potential burden of congenital infection and the importance of evaluating early screening approaches.

Japan

According to Masatoki Kaneko et al. (2023), a prospective cohort study involving 1,163 pregnant women reported a congenital CMV prevalence of 0.4% in the study population. Maternal CMV seroprevalence was 82.5%, and congenital infections occurred following both primary and nonprimary maternal infections.

India

According to Vaishali Rahangdale et al. (2026), approximately 80%–90% of adults in India are seropositive for CMV immunoglobulin G antibodies. The reported prevalence of congenital CMV infection in Indian studies is approximately 1.2% among neonates, while birth prevalence across developing countries, including India, ranges from 0.6% to 6.1% of live births.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

Across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India, opportunities exist to improve congenital CMV awareness, early detection, and monitoring of high-risk populations. The reported congenital infection burden highlights the importance of evaluating newborn screening strategies and improving recognition of maternal infection. In transplant settings, improved viral monitoring and preventive management may help address complications associated with CMV reactivation. India presents a notable epidemiological opportunity because of its high adult seropositivity and reported congenital infection burden. However, comparative regional market data are needed to establish growth rankings and quantify unmet needs.

Cytomegalovirus (CMV) Infection: Treatment Overview

Cytomegalovirus (CMV) infection treatment depends on disease severity, immune status, and clinical presentation. Antiviral medications, including ganciclovir and valganciclovir, are commonly used to manage significant CMV disease, particularly in immunocompromised patients and selected infants with symptomatic congenital infection. Foscarnet and cidofovir may be considered in certain cases of antiviral resistance or intolerance. Letermovir is used for prophylaxis in selected transplant recipients. Monitoring viral load, assessing treatment response, and implementing appropriate preventive strategies are important components of antiviral therapy and CMV management.

Key Questions Answered

  • What is the current and projected burden of cytomegalovirus (CMV) infection across the 8 major markets?
  • Which countries across the 8 major markets account for the highest cytomegalovirus (CMV) infection patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of cytomegalovirus (CMV) infection across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of cytomegalovirus (CMV) infection across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of cytomegalovirus (CMV) infection across the 8 major markets?
  • How do major comorbidities and risk factors influence cytomegalovirus (CMV) infection epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of cytomegalovirus (CMV) infection across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the cytomegalovirus (CMV) infection landscape across the 8 major markets?
  • Which therapeutic areas linked to cytomegalovirus (CMV) infection are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the cytomegalovirus (CMV) infection epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on cytomegalovirus (CMV) infection epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for cytomegalovirus (CMV) infection across the 8 major markets?

Scope of the Cytomegalovirus (CMV) Infection Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cytomegalovirus (CMV) infection based on several factors.
  • Cytomegalovirus (CMV) Infection Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The cytomegalovirus (CMV) infection report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Hepatitis D Epidemiology Forecast

Hepatitis D Pipeline Analysis

Hepatitis B Epidemiology Forecast

Hepatitis C Epidemiology

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us